NovaBay (NBY) Short-Term Debt to Equity

NovaBay Pharmaceuticals (NBY) is expanding Avenova eyelid hygiene sales through online platforms and AI marketing to reduce costs. The company develops ophthalmological products by leveraging predictable pharmacy demand. This chart's price indicator demonstrates a metric at 0.34. However, declining antiseptic margins and the need for debt restructuring create significant risks for the business's future operational stability.

This ratio measures the proportion of short-term liabilities within the equity structure, determining the company's level of dependence on operational debt financing. Analyzing the dynamics of the short-term debt load allows for an assessment of the liquidity risk for NovaBay Pharmaceuticals (NBY) while scaling the Avenova brand in the ophthalmology market, confirming the business's ability to develop the blepharitis treatment segment without critical pressure from current debts.